liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Intratunical Injection of Human Adipose Tissue-Derived Stem Cells Restores Collagen III/IRatio in a Rat Model of Chronic Peyronies Disease
Univ Leuven, Belgium; Univ Coll London Hosp, England; IRCCS Osped San Raffaele, Italy.
Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för läkemedelsforskning. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Diagnostikcentrum, Klinisk farmakologi. Lund Univ, Sweden.
Univ Leuven, Belgium.
Univ Leuven, Belgium; Airlangga Univ, Indonesia.
Visa övriga samt affilieringar
2019 (Engelska)Ingår i: SEXUAL MEDICINE, ISSN 2050-1161, Vol. 7, nr 1, s. 94-103Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Introduction: Previous studies have shown that the injection of adipose tissue-derived stem cells (ADSCs) into the tunica albuginea (TA) during the active phase of Peyronies disease (PD) prevents the development of fibrosis. Aim: To investigate, using an animal model, whether local injection of human ADSCs (hADSCs) can alter the degree of fibrosis in the chronic phase of PD. Methods: 27 male, 12-week-old rats were divided into 3 equal groups: sham, PD without treatment, and PD treated with hADSCs 1 month after disease induction. Sham rats underwent 2 injections of vehicle into the TA 1 month apart. PD rats underwent transforming growth factor beta 1 (TGF beta 1) injection and injection of vehicle 1 month later. PD-hADSC rats underwent TGF beta 1 injection followed by 1 million hADSCs 1 month later. 1 week after treatment, n = 3 animals/group were euthanized, and the penises were harvested for quantitative polymerase chain reaction. 1 month after treatment, the other animals, n = 6 per group, underwent measurement of intracavernous pressure (ICP) and mean arterial pressure (MAP) during electrostimulation of the cavernous nerve. After euthanasia, penises were again harvested for histology and Western blot. Main Outcome Measure: The primary outcome measures included (a) gene expression at one week post-injection; (b) measurement of ICP/MAP upon cavernous nerve stimulation as a measure of erectile function; (c) elastin, collagen I and III protein expression; and (d) Histomorphometric analysis of the penis. Means where compared by analysis of variance (ANOVA) followed by a Student-Newman-Keuls test for post hoc comparisons or Mann-Whitney test when applicable. Results: No significant difference was noted in ICP or ICP/MAP in response to cavernous nerve electrostimulation between the 3 groups at 2.5, 5, and 7.5 V (Pamp;gt;.05 for all voltages). PD animals developed tunical and subtunical areas of fibrosis with a significant upregulation of collagen III protein. The collagen III/I ratio was higher in the PD (4.6 +/- 0.92) group compared with sham (0.66 +/- 0.18) and PD-hADSC (0.86 +/- 0.06) groups (Pamp;lt;.05) These fibrotic changes were prevented when treated with hADSCs. Compared with PD rats, PD-hADSC rats demonstrated a decreased expression of several fibrosis-related genes. Conclusion: Injection of hADSCs reduces collagen III expression in a rat model of chronic PD. Copyright (C) 2018, International Society for Sexual Medicine. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Ort, förlag, år, upplaga, sidor
ELSEVIER SCI LTD , 2019. Vol. 7, nr 1, s. 94-103
Nyckelord [en]
Peyronies Disease; Stem Cell; Adipose Stem Cell; Fibrosis
Nationell ämneskategori
Oto-rino-laryngologi
Identifikatorer
URN: urn:nbn:se:liu:diva-155557DOI: 10.1016/j.esxm.2018.09.003ISI: 000460015200013PubMedID: 30503767OAI: oai:DiVA.org:liu-155557DiVA, id: diva2:1299385
Anmärkning

Funding Agencies|European Society for Sexual Medicine (ESSM); European Urological Scholarship Programme (EUSP); NIHR Biomedical Research Centre, University College London Hospital

Tillgänglig från: 2019-03-26 Skapad: 2019-03-26 Senast uppdaterad: 2019-10-01

Open Access i DiVA

fulltext(2325 kB)18 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 2325 kBChecksumma SHA-512
dd2d6514d2bcf0be32d4c6a313147adb13e9185eaeac7ca737569d11c70b7d3e3e94d616677f7ab9ddfd06388abf75fed993ac59985afee44115fed2935cbfb3
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMed

Sök vidare i DiVA

Av författaren/redaktören
Hedlund, Petter
Av organisationen
Avdelningen för läkemedelsforskningMedicinska fakultetenKlinisk farmakologi
Oto-rino-laryngologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 18 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 53 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf